John Geddes - Curriculum Vitae#
CURRENT POSITIONS:
1. WA Handley Professor of Psychiatry, University of Oxford
2. Fellow, Merton College, Oxford (from Nov 1st 2021)
3. Director, NIHR Oxford Health Biomedical Research Centre, April 2017 - present
4. Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust, Oxfordshire, UK 1995 - present
PREVIOUS POSITIONS:
- Director, NIHR Oxford Cognitive Health Clinical Research Facility, Oxford University Hospitals NHS Foundation Trust 2011 - 2019
- Director of R&D, Oxford Health NHS Foundation Trust 2011 - June 2021
- Professor of Epidemiological Psychiatry and Senior Clinical Research Fellow, University of Oxford 2002 - Oct 31st 2021
- Head of Department of Psychiatry, University of Oxford 2011 - Sept 30th 202
QUALIFICATIONS:
- 1985 MB ChB, University of Leeds
- 1989 Member, Royal College of Psychiatrists
- 1993 MD, University of Leeds
- 2000 Fellow, Royal College of Psychiatrists
ORCID: 0000-0002-5281-5960; H-index: Scopus 75
CURRENT RESEARCH GRANTS:
1. 2022-2027 Principal Investigator/Director NIHR Oxford Health Biomedical Research Centre (£35M)
2. 2020-2021 Co-applicant: DHSC/UKRI COVID-19 Rapid Response Initiative: Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID) £8.4 million
3. 2018-2023: Co-investigatorNIHR Efficacy and Mechanism Evaluation Pramipexole in Treatment resistant depression (PAX-D) £2.5 million
4. 2018-2023 Co-Applicant: NIHR Health Technology Assessment Pramipexole in Bipolar Depression (PAX-BD) RCT £1.5 million
5. 2017-2022 Co-Applicant NIHR Programme Grant for Applied Research TACKling chronic depression - adapting and testing a technology supported patient-centred and solution-focused intervention (DIALOG+) for people with chronic depression (TACK) £2,487,369
6. 2017-2022 Co-Applicant Canadian Institutes of Health Research (CIHR) Predicting the onset of bipolar disorder: A longitudinal high-risk study 950,000 CAD
7. 2018-2021 Co-Applicant NIHR Invention for Innovation (i4i) Immersive virtual reality to transform the lives of patients with psychosis £3,994,595
8. 2017-2022 Co-Applicant NIHR Health Technology Assessment Lithium versus Quetiapine in Depression (LQD) RCT £1.5 million
